Brought to you by 
Amgen to acquire Synergen for $239.6 million
22 Jan 2010
Executive Summary
Amgen agreed to acquire Synergen for $239.6 million, paying $9.25 per share for Synergen's 25.9 million outstanding shares. An additional 2 million option shares may be acquired, raising the cost of the buyout to $258 million.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com